+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hypolipidemics Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • November 2023
  • Region: Global
  • The Business Research Company
  • ID: 5734963
The hypolipidemics market size has grown steadily in recent years. It will grow from $28.65 billion in 2023 to $29.93 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of hyperlipidemia, shifts in lifestyle choices, a growing aging population, heightened awareness and screening for lipid disorders, and the dominant use of statins as a common treatment approach. These factors collectively contributed to the growth of the hypolipidemic drug market in the past.

The hypolipidemics market size is expected to see steady growth in the next few years. It will grow to $34.93 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The anticipated growth in the forecast period can be attributed to several factors, including the adoption of personalized medicine, the expansion of the patient pool, increased market opportunities in emerging economies, government initiatives to address lipid disorders, and the development of combination therapies. Furthermore, significant trends expected in the forecast period include a shift from managing LDL to non-HDL cholesterol, the integration of digital health and telemedicine, market consolidation and heightened competition, and a growing emphasis on patient-centric approaches in the hypolipidemic drug market.

Changes in dietary habits and lifestyle choices have been significant drivers in the growth of the hypolipidemic drugs market. Unhealthy food consumption, increased smoking, and alcohol intake have resulted in higher cholesterol levels in individuals. The World Health Organization's 2021 data indicates that cardiovascular diseases (CVDs) are a primary cause of global mortality, claiming approximately 17.9 million lives annually. The escalating levels of cholesterol due to lifestyle changes have led to an increased demand for hypolipidemic drugs as they aid in reducing cholesterol levels.

The primary product categories of hypolipidemic drugs include cholic acid regulators, HMG-CoA reductase inhibitors, adenylate cyclase inhibitors, nicotinic acid drugs, and various other types. HMG-CoA reductase inhibitors, in particular, are lipid-lowering medications widely employed for both primary and secondary prevention of coronary heart disease. These drugs are used and distributed through hospitals, clinics, pharmacies, and cardiology centers. Various drug types within this category include statins, bile acid sequestrants, cholesterol absorption inhibitors, PCSK9 inhibitors, and other formulations.

The hypolipidemic drugs market research report is one of a series of new reports that provides hypolipidemic drugs market statistics, including hypolipidemic drugs industry global market size, regional shares, competitors with a hypolipidemic drugs market share, detailed hypolipidemic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hypolipidemic drugs industry. This hypolipidemic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rising occurrences of obesity are anticipated to propel the hypolipidemic drugs market's growth trajectory. Obesity, defined as having a body mass index (BMI) of 30 or higher, often results from taste modulators altering physiological responses to food, contributing to excessive weight gain. Hypolipidemic drugs play a role in addressing obesity by lowering heightened cholesterol levels, which can pose cardiovascular risks to individuals with excess body fat. The World Health Organization, as of March 2022, reported that an estimated 650 million adults, 340 million teenagers, and 39 million children are affected by obesity, with these numbers steadily increasing. The projection suggests that by 2025, approximately 167 million adults and children will be classified as overweight or obese. Therefore, the increasing prevalence of obesity is a driving force behind the hypolipidemic drug market.

The escalating use of biologics acts as a major deterrent hindering the growth of the hypolipidemic drugs market. Biologics, derived from living organisms, diverge from chemically synthesized drugs and have been gaining preference due to side effects associated with chemical drugs. This shift towards hypolipidemic biologic medicines has impacted the sales of traditional chemically synthesized hypolipidemic drugs, affecting their market growth. For example, according to Harvard Medical School, 10%-29% of individuals using hypolipidemic drugs, such as cholesterol-lowering statins, experience muscle aches and pains. The introduction of PCSK9 Inhibitors, a type of hypolipidemic biologic, has been in use since 2015 to reduce LDL cholesterol levels, exemplified by the FDA approval of Amgen's Repatha for hypolipidemia treatment.

Companies within this market sector are increasingly focusing on leveraging wearable data in clinical trials to enhance the speed, efficiency, and overall cost reduction of these trials. The continuous data collection from patients through wearable technologies can reduce the need for frequent site visits, leading to improved patient retention rates and overall efficiency in clinical trials. Wearables assist in addressing patient recruitment challenges, enabling real-time monitoring and data accuracy, thereby facilitating earlier decision-making during clinical trials. Pharmaceutical giants like Sanofi and Pfizer have already invested in wearable technology for treating hypolipidemia.

The approval process for hypolipidemic drugs by EU agencies generally takes 6 to 12 months and demands a single submission of the complete registration dossier, unlike the phased submissions accepted by the US FDA. While the FDA evaluates each technical section within six months, the process may be extended if queries or issues arise. However, simultaneous assessments of the technical sections require manufacturers to plan and identify time-consuming steps to estimate approval dates effectively. In the EU region, the licensing validity and application renewals add significant regulatory complexity, compelling manufacturers to communicate and plan effectively to minimize costs and reduce timelines.

Key companies in the hypolipidemic drugs market are directing their efforts towards introducing lipid-lowering medications like Brillo to gain a competitive advantage. Brillo is an oral lipid-lowering drug featuring bempedoic acid, a first-in-class compound designed to reduce low-density lipoprotein (LDL) cholesterol, a primary risk factor for cardiovascular diseases. In May 2022, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, unveiled Brillo in India. This medication utilizes bempedoic acid, offering a unique mode of action distinct from existing lipid-lowering agents. Brillo is prescribed for individuals with genetically high cholesterol or confirmed heart disease, especially when cholesterol levels remain high despite lifestyle modifications and the highest acceptable statin doses.

Major companies operating in the hypolipidemics market include Abbott Laboratories Limited, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited, Chunghwa Chem Syn& Biotech Co. Ltd., Concord Biotech Limited, Croda Europe Limited, Daiichi Sankyo Company Limited, Dr. Reddy’s Laboratories Ltd., DSM Sinochem Pharma India Pvt. Ltd., Hikal Chemicals Industries Limited, Ipca Laboratories Ltd., Lek Pharmaceuticals D.d, Lupin Limited, Merck Sharp & Dohme B.V, Mylan N.V, Nexchem Pharmaceutical Co. Ltd., Olon S.p.A, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zhejiang Jiangbei Pharma Co. Ltd., Moehs Iberica S.L. ES, Pfizer Inc., Recordati S.p.A., AstraZeneca Plc, Amgen Plc, Daiichi Sankyo Company Limited, Kowa Company Ltd., Sanofi-Aventis, Novartis AG, Viatris Inc., Pfizer Inc., GlaxoSmithKline plc, Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Jubilant Life Sciences Limited, Hetero Drugs Limited, Ind-Swift Laboratories Ltd., Intas Pharmaceuticals Ltd., Unichem Laboratories Ltd.

North America was the largest region in the hypolipidemic drugs market in 2023. The Middle East is expected to be the fastest-growing region in the hypolipidemic drugs market during the forecast period. The regions covered in the hypolipidemics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hypolipidemics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The hypolipidemic drugs market consists of sales of cholesterol absorption inhibitors, bile acid sequestrants, and fibric acid derivatives. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Hypolipidemics Market Characteristics3. Hypolipidemics Market Trends And Strategies
4. Hypolipidemics Market - Macro Economic Scenario
4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market
5. Global Hypolipidemics Market Size and Growth
5.1. Global Hypolipidemics Market Drivers and Restraints
5.1.1. Drivers Of The Market
5.1.2. Restraints Of The Market
5.2. Global Hypolipidemics Historic Market Size and Growth, 2018 2023, Value ($ Billion)
5.3. Global Hypolipidemics Forecast Market Size and Growth, 2023 2028, 2033F, Value ($ Billion)
6. Hypolipidemics Market Segmentation
6.1. Global Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cholic Acid Regulator
  • HMG-CoA Reductase Inhibitors
  • Adenylate Cyclase Inhibitors
  • Nicotinic Acid Drugs
6.2. Global Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • PCSK9 Inhibitors
  • Other Drug Types
6.3. Global Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital
  • Clinics
  • Pharmacy
  • Cardiovasology
7. Hypolipidemics Market Regional And Country Analysis
7.1. Global Hypolipidemics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Hypolipidemics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Hypolipidemics Market
8.1. Asia-Pacific Hypolipidemics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Hypolipidemics Market
9.1. China Hypolipidemics Market Overview
9.2. China Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Hypolipidemics Market
10.1. India Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Hypolipidemics Market
11.1. Japan Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.2. Japan Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Hypolipidemics Market
12.1. Australia Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Hypolipidemics Market
13.1. Indonesia Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Hypolipidemics Market
14.1. South Korea Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.2. South Korea Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Hypolipidemics Market
15.1. Western Europe Hypolipidemics Market Overview
15.2. Western Europe Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Hypolipidemics Market
16.1. UK Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Hypolipidemics Market
17.1. Germany Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Hypolipidemics Market
18.5. France Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Hypolipidemics Market
19.9. Italy Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Hypolipidemics Market
20.13. Spain Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Hypolipidemics Market
21.1. Eastern Europe Hypolipidemics Market Overview
21.2. Eastern Europe Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Hypolipidemics Market
22.1. Russia Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Hypolipidemics Market
23.1. North America Hypolipidemics Market Overview
23.2. North America Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Hypolipidemics Market
24.1. USA Hypolipidemics Market Overview
24.2. USA Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Hypolipidemics Market
25.1. Canada Hypolipidemics Market Overview
25.2. Canada Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Hypolipidemics Market
26.1. South America Hypolipidemics Market Overview
26.2. South America Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Hypolipidemics Market
27.1. Brazil Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Hypolipidemics Market
28.1. Middle East Hypolipidemics Market Overview
28.2. Middle East Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Hypolipidemics Market
29.1. Africa Hypolipidemics Market Overview
29.2. Africa Hypolipidemics Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Hypolipidemics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Hypolipidemics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Hypolipidemics Market Competitive Landscape And Company Profiles
30.1. Hypolipidemics Market Competitive Landscape
30.2. Hypolipidemics Market Company Profiles
30.2.1. Abbott Laboratories Limited
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Apotex Fermentation Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Biocon Limited
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Cadila Healthcare Limited
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Chunghwa Chem Syn& Biotech Co. Ltd.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Global Hypolipidemics Market Competitive Benchmarking32. Global Hypolipidemics Market Competitive Dashboard33. Key Mergers And Acquisitions In The Hypolipidemics Market
34. Hypolipidemics Market Future Outlook and Potential Analysis
34.1 Hypolipidemics Market In 2028 - Countries Offering Most New Opportunities
34.2 Hypolipidemics Market In 2028 - Segments Offering Most New Opportunities
34.3 Hypolipidemics Market In 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer

Executive Summary

Hypolipidemics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypolipidemics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • All data from the report will also be delivered in an excel dashboard format.

Description:

Where is the largest and fastest growing market for hypolipidemics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

  • Markets Covered: 1) By Product Type: Cholic Acid Regulator; HMG-CoA Reductase Inhibitors; Adenylate Cyclase Inhibitors; Nicotinic Acid Drugs; Other Types; 2) By Drug Type: Statins; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; PCSK9 Inhibitors; Other Drug Types; 3) By Application: Hospital; Clinics; Pharmacy; Cardiovasology
  • Companies Mentioned: Abbott Laboratories Limited; Apotex Fermentation Inc.; Biocon Limited; Cadila Healthcare Limited; Chunghwa Chem Syn& Biotech Co. Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories Limited
  • Apotex Fermentation Inc.
  • Biocon Limited
  • Cadila Healthcare Limited
  • Chunghwa Chem Syn& Biotech Co. Ltd.
  • Concord Biotech Limited
  • Croda Europe Limited
  • Daiichi Sankyo Company Limited
  • Dr. Reddy’s Laboratories Ltd.
  • DSM Sinochem Pharma India Pvt. Ltd.
  • Hikal Chemicals Industries Limited
  • Ipca Laboratories Ltd.
  • Lek Pharmaceuticals D.d
  • Lupin Limited
  • Merck Sharp & Dohme B.V
  • Mylan N.V
  • Nexchem Pharmaceutical Co. Ltd.
  • Olon S.p.A
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zhejiang Jiangbei Pharma Co. Ltd.
  • Moehs Iberica S.L. ES
  • Pfizer Inc.
  • Recordati S.p.A.
  • AstraZeneca Plc
  • Amgen Plc
  • Daiichi Sankyo Company Limited
  • Kowa Company Ltd.
  • Sanofi-Aventis
  • Novartis AG
  • Viatris Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Cipla Limited
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited
  • Wockhardt Limited
  • Alembic Pharmaceuticals Limited
  • Jubilant Life Sciences Limited
  • Hetero Drugs Limited
  • Ind-Swift Laboratories Ltd.
  • Intas Pharmaceuticals Ltd.
  • Unichem Laboratories Ltd.

Methodology

Loading
LOADING...